Kennen MacKay
Stock Analyst at RBC Capital
(2.26)
# 2,569
Out of 4,712 analysts
39
Total ratings
46.15%
Success rate
8.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kennen MacKay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Maintains: Outperform | $4 → $5 | $2.82 | +77.30% | 1 | Apr 17, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $40 → $42 | $34.19 | +22.84% | 3 | Jun 27, 2023 | |
| AMGN Amgen | Maintains: Sector Perform | $224 → $236 | $264.49 | -10.77% | 4 | Aug 5, 2022 | |
| EXEL Exelixis | Maintains: Outperform | $32 → $31 | $33.82 | -8.34% | 2 | Nov 3, 2021 | |
| ADCT ADC Therapeutics | Maintains: Outperform | $33 → $34 | $2.01 | +1,591.54% | 2 | Nov 3, 2021 | |
| PRTA Prothena Corporation | Maintains: Outperform | $59 → $82 | $15.40 | +432.47% | 5 | Sep 30, 2021 | |
| PBYI Puma Biotechnology | Maintains: Sector Perform | $13 → $6 | $3.02 | +98.68% | 2 | Aug 6, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Sector Perform | $87 → $88 | $66.63 | +32.07% | 9 | Jul 29, 2021 | |
| NRIX Nurix Therapeutics | Initiates: Outperform | $42 | $19.57 | +114.61% | 1 | Apr 30, 2021 | |
| MESO Mesoblast | Initiates: Sector Perform | $48 | $17.02 | +182.02% | 1 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $175 | $5.68 | +2,980.99% | 2 | May 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $23 | $42.41 | -45.77% | 3 | Apr 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | n/a | $13.89 | - | 3 | Apr 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $0.60 | +2,252.94% | 1 | Sep 15, 2017 |
Nuvation Bio
Apr 17, 2024
Maintains: Outperform
Price Target: $4 → $5
Current: $2.82
Upside: +77.30%
Agios Pharmaceuticals
Jun 27, 2023
Maintains: Outperform
Price Target: $40 → $42
Current: $34.19
Upside: +22.84%
Amgen
Aug 5, 2022
Maintains: Sector Perform
Price Target: $224 → $236
Current: $264.49
Upside: -10.77%
Exelixis
Nov 3, 2021
Maintains: Outperform
Price Target: $32 → $31
Current: $33.82
Upside: -8.34%
ADC Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $33 → $34
Current: $2.01
Upside: +1,591.54%
Prothena Corporation
Sep 30, 2021
Maintains: Outperform
Price Target: $59 → $82
Current: $15.40
Upside: +432.47%
Puma Biotechnology
Aug 6, 2021
Maintains: Sector Perform
Price Target: $13 → $6
Current: $3.02
Upside: +98.68%
BioMarin Pharmaceutical
Jul 29, 2021
Maintains: Sector Perform
Price Target: $87 → $88
Current: $66.63
Upside: +32.07%
Nurix Therapeutics
Apr 30, 2021
Initiates: Outperform
Price Target: $42
Current: $19.57
Upside: +114.61%
Mesoblast
Oct 22, 2020
Initiates: Sector Perform
Price Target: $48
Current: $17.02
Upside: +182.02%
May 8, 2020
Maintains: Outperform
Price Target: $275 → $175
Current: $5.68
Upside: +2,980.99%
Apr 3, 2019
Upgrades: Outperform
Price Target: $18 → $23
Current: $42.41
Upside: -45.77%
Apr 4, 2018
Downgrades: Sector Perform
Price Target: n/a
Current: $13.89
Upside: -
Sep 15, 2017
Initiates: Outperform
Price Target: $14
Current: $0.60
Upside: +2,252.94%